Keith J. Kendall
2020
In 2020, Keith J. Kendall earned a total compensation of $1.3M as Chief Executive Officer at Aquestive Therapeutics, a 51% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $450,368 |
|---|---|
| Option Awards | $259,364 |
| Salary | $550,000 |
| Other | $30,686 |
| Total | $1,290,418 |
Kendall received $550K in salary, accounting for 43% of the total pay in 2020.
Kendall also received $450.4K in non-equity incentive plan, $259.4K in option awards and $30.7K in other compensation.
Rankings
In 2020, Keith J. Kendall's compensation ranked 7,520th out of 13,090 executives tracked by ExecPay. In other words, Kendall earned more than 42.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,520 out of 13,090 | 43rd |
Division Manufacturing | 3,163 out of 5,617 | 44th |
Major group Chemicals And Allied Products | 1,273 out of 2,248 | 43rd |
Industry group Drugs | 1,100 out of 1,948 | 44th |
Industry Pharmaceutical Preparations | 821 out of 1,453 | 44th |
Source: SEC filing on May 5, 2021.
Kendall's colleagues
We found two more compensation records of executives who worked with Keith J. Kendall at Aquestive Therapeutics in 2020.